Astellas Beats H1 Forecast on Strategic Product Growth, Cost Controls

To read the full story

• Sign In
• Subscribe

Related Article

• Astellas on Track to Hit 30% Margin Goal Early after Strong H1 Scorecards
  November 5, 2026

• Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
  April 28, 2026

• Astellas Assembles Task Team to Assess US Tariff Risks
  July 31, 2025

• Astellas Gears Up for Xtandi Patent Cliff with Next-Gen Assets, Cost Cuts
  April 28, 2025

• Astellas Slashes Full-Year Profit Forecasts on Impairment Loss of Izervay and More
  January 27, 2025

• Astellas Records 22% Revenue Growth in 1H Riding on Strategic Assets
  October 31, 2024

• Xtandi’s Global Sales Surge Nearly 30% in April-June: Astellas
  August 2, 2024

• Astellas’ FY2023 Operating Profit Tumbles 80% Due to Iveric Bio Buyout
  April 26, 2024

• Astellas Slashes FY2023 Profit Forecasts on Gene Therapy Impairment Loss
  April 15, 2024

• Astellas Slashes FY2023 Veozah Forecast as Vertical Start-Up Plan Stumbles
  February 6, 2024

• Astellas Squeaks Out Sales Rise as FX, Mainstay Growth Offset Generic Hit
  November 2, 2023

• Astellas’ Q1 Sales Skid on Lexiscan Generic Erosion, but Full-Year Growth Expected with Hot Flash Med
  August 2, 2023

• Astellas Logs 17.2% Sales Growth in FY2022 on Xtandi, but Profits Fall
  April 28, 2023

• Astellas’ April-December Sales Up 17% on FX Tailwind; Xtandi Slows in US but Brisk in Japan
  February 7, 2023

• Astellas’ Half-Year Revenue Up 17% on FX Boon; Xtandi US Sales Stall
  November 2, 2022

• Astellas’ Earnings Hit by FX as Cost Rate Worsens on Overseas Inventories
  August 2, 2022

• Astellas Logs 1st Sales Growth in 3 Years in FY2021; Chairman Hatanaka to Bow Out
  April 28, 2022

• Astellas to Write Off Massive Losses over AT132, DMD Gene Therapies
  April 25, 2022

• Astellas Sees Surge in 9-Month Revenue on Xtandi Growth, US Market Recovery
  February 3, 2022

• Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
  November 1, 2021

• Astellas Logs Sales Growth in Q1, but Profits Drop Sharply on Write-Offs
  August 2, 2021

• Xtandi Bullish, but Astellas Sales Wane 3.9% on Deal Wind-Ups; Profits Dip after Gene Therapy Trial Hold
  April 28, 2021

• Astellas’ 9-Month Earnings Stumble on Celecox Generic Erosion, Sales Pact Terminations
  February 1, 2021

• Astellas Earnings Flounder in April-September on LOEs, Deal Terminations
  November 2, 2020

• Astellas’ Q1 Sales Falter 8% on Deal Terminations, COVID-19
  August 5, 2020

• Astellas Sees New Drug Growth Counter Off-Patent Dip in FY2019
  May 15, 2020